Hydroxychloroquine is used to prevent or treat malaria caused by mosquito bites. The United States Center for Disease Control provides updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs.
This medication is also used to treat certain auto-immune diseases (lupus, rheumatoid arthritis). It belongs to a class of medications known as disease-modifying antirheumatic drugs. It can reduce skin problems in lupus and prevent swelling/pain in arthritis.
How to use Hydroxychloroquine SULFATE
Take this medication by mouth, usually with food to prevent stomach upset, exactly as directed by your doctor. The dosage and length of treatment are based on your medical condition and response to treatment. In children, the dosage is also based on weight.
Aims: Studies have indicated that chloroquine (CQ) shows antagonism against COVID-19 in vitro. However, evidence regarding its effects on patients is limited. This study aims to evaluate the efficacy of hydroxychloroquine (HCQ) in the treatment of patients with COVID-19.
62 patients that suffered from COVID-19 were admitted to the Renmin Hospital of Wuhan University. All participants were randomized in a parallel-group trial. 31 patients were assigned to receive an additional 5-day HCQ (400 mg/d) treatment, Time to clinical recovery (TTCR), clinical characteristics, and radiological results were assessed at baseline and 5 days after treatment to evaluate the effect of HCQ.
For the 62 COVID-19 patients, 46.8% (29 of 62) were male and 53.2% (33 of 62) were female, the mean age was 44.7 (15.3) years. No difference in the age and sex distribution between the control group. But for TTCR, the body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group.
Besides, a larger proportion of patients with improved pneumonia in the HCQ treatment group (80.6%, 25 of 31). All 4 patients progressed to severe illness that occurred in the control group.
However, there were 2 patients with mild adverse reactions in the HCQ treatment group. Among patients with COVID-19, the use of HCQ could significantly shorten TTCR and promote the absorption of pneumonia.